Theis Terwey

Theis Terwey is a Berlin-based physician, biotech entrepreneur, and angel investor. Creative Destruction Lab describes him as having more than 20 years of experience across academic medicine, drug development, biopharma investment, and company building. He holds a Doctor medicinae, specialist certification in internal medicine, and a Habilitation from Charité – University Medicine Berlin.

Terwey’s early career combined clinical medicine and research. Public biographical material from GH Research says he served in roles at NB Capital Research GmbH, first as Medical Advisor from 2009 to 2012 and then Managing Director from 2012 to 2015. He later became Partner at NB Capital ApS from 2015 to 2020, where the focus was public and private investments across pharmaceutical-development stages.

He co-founded GH Research, a Dublin-based clinical-stage biopharmaceutical company focused on mebufotenin therapies for psychiatric and neurological disorders. GH Research SEC filings state that he was a director from the company’s founding in 2018 to 2020 and served as CEO from May 2021 until September 2024. During his tenure, GH Research advanced through IPO and into Phase 2b clinical development; Creative Destruction Lab reports that the company raised more than $300 million across multiple rounds.

In September 2024, GH Research announced that Dr. Velichka “Villy” Valcheva succeeded Terwey as CEO. Since then, Terwey’s public investing profile has centered on angel and healthcare-network roles: Founder and Managing Director of n.cour projects GmbH, angel investor with Springboard Health Angels and Business Angels Club Berlin-Brandenburg, CDL-Berlin Health mentor, and advisor with SPARK-BIH.

• Terwey appears to focus on companies where clinical development, mechanism, and commercial validation matter more than generic healthcare narratives.
• His strongest documented domain is biopharma: academic medicine, internal medicine, oncology/hematology research, drug development, public/private pharmaceutical investing, and company building.
• Through Springboard Health Angels, he is associated with a cross-border healthcare investor network focused on health-tech and life-science startups in Europe and the U.S.
• His Captain T Cell comment shows how he evaluates biotech opportunities: he highlighted a “de-risked and commercially validated target,” convincing preclinical data, and a potentially superior approach versus marketed solid-tumor cell therapies.
• His NB Capital background suggests comfort across the full biopharma lifecycle, from seed/private company formation to public markets and exits.
• Avoid unsupported claims that “pharma will pay”; Springboard activity around Terwey’s network emphasizes that founders should map the specific pharma buyer, budget holder, and adoption path.